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Background For safety assessment in clinical trials, adverse events (AEs) are reported for the drug under evaluation
and compared with AEs in the placebo group. Little is known about the nature of the AEs associated with clinical tri-
als of SARS-CoV-2 vaccines and the extent to which these can be traced to nocebo effects, where negative treatment-
related expectations favor their occurrence.
Methods In our systematic review, we compared the rates of solicited AEs in the active and placebo groups of SARS-
CoV-2 vaccines approved by the Western pharmaceutical regulatory agencies.
We implemented a search strategy to identify trial-III studies of SARS-CoV-2 vaccines through the PubMed data-
base. We adopted the PRISMA Statement to perform the study selection and the data collection and identified three
trial: two mRNA-based (38403 participants) and one adenovirus type (6736 participants).
Findings Relative risks showed that the occurrence of AEs reported in the vaccine groups was higher compared with
the placebo groups. The most frequently AEs in both groups were fatigue, headache, local pain, as injection site reac-
tions, and myalgia. In particular, for first doses in placebo recipients, fatigue was reported in 29% and 27% in
BNT162b2 and mRNA-1273 groups, respectively, and in 21% of Ad26.COV2.S participants. Headache was reported
in 27% in both mRNA groups and in 24% of Ad26.COV2.S recipients. Myalgia was reported in 10% and 14% in
mRNA groups (BNT162b2 and mRNA-1273, respectively) and in 13% of Ad26.COV2.S participants. Local pain was
reported in 12% and 17% in mRNA groups (BNT162b2 and mRNA-1273, respectively), and in 17% of Ad26.COV2.S
recipients. These AEs are more common in the younger population and in the first dose of placebo recipients of the
mRNA vaccines.
Interpretation Our results are in agreement with the expectancy theory of nocebo effects and suggest that the AEs
associated with COVID-19 vaccines may be related to the nocebo effect.
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www.thelancet.com Vol xx Month xx, 2021Introduction
Adverse events (AEs) of drugs are a central feature of
the information that goes into clinical treatment deci-
sions. It is known that by analyzing safety outcomes in
placebo groups, randomized clinical trials (RCTs) pro-
vide a perspective for understanding the role of negative
expectations in treatment outcomes − the nocebo effect,1
Research in context
Evidence before this study
Adverse events (AEs) of drugs are a central feature of
safety assessment information. It is known that random-
ized clinical trials provide a perspective for understand-
ing the role of negative expectations in the active drug
group and the AEs of a placebo treatment described as
a nocebo effect.
Added value of this study
Little is known about the nature of the AEs associated
with clinical trials of SARS-CoV-2 vaccines and the
extent to which these are nocebo effects, where nega-
tive treatment-related expectations favor their occur-
rence. To bridge this gap, our study aims to analyze the
phase III safety data of vaccines approved to date with
respect to the solicited AE profiles in the active and pla-
cebo groups. We found that AEs such as fatigue, head-
ache, and pain (as local injection site reaction and
myalgia) were the most commonly reported in both the
active drug and the placebo arms, although in active
vaccine arms they were higher.
The AEs of fatigue, headache, and pain are more
common in the younger population and in the first
dose of mRNA placebo recipients.
Implication of all the available evidence
Our results suggest that a substantial proportion of soli-
cited AEs are not a result of the vaccine per se but are,
in fact, nocebo effects. Awareness of the nocebo effect
in placebo recipients of the vaccine trials may lead to a
greater participation in the COVID-19 immunization and
to a greater protection from infection.
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originally introduced to describe the negative effects of a
placebo treatment.1
Different contextual and patients related factors lead-
ing to nocebo effects have been identified.2,3 Placebo
groups from RCTs provide the data to analyze nocebo
effects in terms of the occurrence of adverse reactions
and treatment non-adherence in term of drop out. In a
RCT, subjects know that they can receive either the
active drug or the placebo and, accordingly, they are
informed about the AEs they may experience. This can
have a significant impact on the experience of associated
discomfort. Indeed, drugs that produce more AEs cause
highest symptomatic effects, even in the placebo
groups,4−8 and consequently higher dropout rates due
to a negative treatment outcome. Significantly, Bene-
detti et al.9 have recently demonstrated an involvement
of hypothalamic-pituitary-adrenal activity and state anxi-
ety in AEs reporting after placebo administration.
AEs may also be related to disease symptoms as
reported for immunization with non-live vaccines. This
highlights that symptoms are not always caused by thevaccine, but may be due to negative expectations and
linked to nocebo risks.10 The reason why these AEs
occur is unclear, and understanding the underlying
mechanisms is an ongoing challenge.
However, to date, no study has assessed the AEs in
the placebo control groups associated with COVID-19
vaccines. With this aim, we conducted an analysis of the
solicited AEs in clinical trials for SARS-CoV-2 vaccines.
We analyzed both active recipients and placebo groups,
in order to test whether any of these AEs might be asso-
ciated with nocebo effects.Methods
We implemented a search strategy to identify through
the PubMed database (https://pubmed.ncbi.nlm.nih.
gov), trial-III studies of SARS-CoV-2 vaccines published
until 1 July 2021. No filter or limits were used. We
adopted the "PRISMA Statement"11 to perform the
study selection and the data collection
(Supplementary Table 1).
We only considered trials approved by Western phar-
maceutical regulatory agencies - i.e. the European Medi-
cine Agency (EMA) or the Food and Drug
Administration (FDA) - as safety data could cross-
checked with results included in trial publications.
As inclusion criteria, we considered studies in which
the placebo control group was treated with a saline solu-
tion and data collected considering the adult population
(> 18 years).
Study selection was performed independently by
three authors (M.A., M.B., G.E.C.), according to the pre-
defined eligibility criteria. Cohen's K was used to assess
the level of agreement in accordance with the inclusion
and exclusion of the studies.
A total of three studies, out of 171, met the inclusion
criteria and thus were included in our analysis (see the
flow chart in Supplementary Figure 1). Risk of Bias of
the three included studies was considered.12,13 Particu-
larly, we analyzed studies concerning three different
vaccines: BNT162b2,14 mRNA-1273,15 and Ad26.COV2.
S.16 We identified ten clinical trials: five were clinical tri-
als with mRNA-based vaccines (BNT162b2: no. two;
mRNA-1273: no. three), and five were clinical trials
using an adenovirus vector vaccine (Ad26.COV2.S).
The trials performed with AZD1222,14 approved only
by the EMA but not by the FDA, were excluded as the
control groups were treated with meningococcal vaccine
for serogroups A, C, W, and Y (MenACWY), or with
MenACWY (as first dose) and saline (as second dose).
Only one trial (COV005) for AZD1222 had adminis-
tered saline in the placebo group; however, this trial was
not included in the interim primary efficacy analyses.
With regard to data abstraction, each of the three
selected studies was coded using a structured coding
scheme, including information on report identification,
methodology, subjects, and treatment.www.thelancet.com Vol xx Month xx, 2021
ArticlesDuring the validity assessment phase, two different
authors (M.B. and G.E.C.) performed the assessment of
methodological quality independently. Disagreements
that occurred in this phase were solved through discus-
sion between all the authors.
Cohen's K used to assess the level of agreement in
accordance with the inclusion and exclusion of the stud-
ies: % agreement 100; Cohen’s K: 1.
The Cochrane Collaboration's tool for assessing risk
of bias12,13 was used in order to consider: [a] selection
bias (concerning ‘sequence generation’ and ‘allocation
concealment’); [b] performance bias (‘blinding of partici-
pants and personnel’); [c] detection bias (‘blinding of
outcome assessment’); [d] attrition bias (‘incomplete
outcome data’); [e] reporting bias (‘selective outcome
reporting’). Particularly, we assessed separately the
domains “incomplete outcome data” and “selective out-
come reporting” for subjects withdrawing due to AEs
and occurrence of AEs (including serious AEs).
Data from the selected trials were extracted by three
authors (M.A., M.B., G.E.C.).
As ascertainment strategy based on the solicited
safety set, for all studies, the AEs were collected in both
vaccine and placebo group arms. For RCTs involving
mRNA technology vaccines, AEs data from both the first
and the second dose were also extracted; whereas, for
RCTs involving the viral vector type vaccine, only AEs
data from the first and unique dose were considered.
Moreover, we also collected the unsolicited adverse reac-
tions (reported within 28 days after the injection) in
terms of severe symptoms (Serious Adverse Events,
SAEs), and deaths in the three selected trials.
Finally, variables such as sample size, gender, age,
withdrawals, diagnosis of COVID-19 and ethnicity, were
also collected from the full analysis sets.
In the selected trials, the AEs were coded according
to the Medical Dictionary for Regulatory Activities
(MedDRA). In each trial, AEs data were reported as the
total number of participants in a specific group, the
number and the percentage of participants with speci-
fied adverse reaction.
Solicited AEs included in the selected trials refer to −
a list of events and symptoms that participants were spe-
cifically asked to record using electronic diaries − within
seven days of inoculation. Solicited AEs were extracted
from the safety set of each study. We only considered
and included in the database AEs that were present in at
least two out of three trials of each vaccine. We identified
eleven categories of solicited AEs, both systemic symp-
toms and injection site reactions, reported in the studies.
In particular, we grouped the terms arthralgia and joint
pain, myalgia and muscle pain, nausea and vomiting,
local erythema and redness, according to MedDRA classi-
fication (Table 1).
Percentages of patients reporting the solicited AEs,
with 95% confidence intervals (CIs), have been
expressed for all reported outcome measures. Non-www.thelancet.com Vol xx Month xx, 2021overlapping CIs of the percentages of AEs indicate sig-
nificant differences among the different categories.
For mRNA vaccines (BNT162b2 and mRNA-1273),
percentages with 95% CIs were calculated for both the
first and the second dose. Moreover, safety data were
also analyzed by taking into account two different age
ranges, as reported in the original trials: (a) BNT162b2:
18-54 years and 55 years and older; (b) mRNA-1273: 18-
64 years and 65 years and older; (c) Ad26.COV2.S (sin-
gle dose): 18-59 years and 60 years and older.
For each study, relative risk (RR) of solicited AEs was
calculated in order to compare vaccine and placebo
groups for all reported symptoms.
The funding source has no roles in study design,
data collection, data analysis, interpretation, and writing
of the report.Results
The risk of bias was generally low in all trials. However,
one study (of BNT162b2 vaccine) presented an unclear
risk concerning performance bias (blinding of partici-
pants and personnel), while an unclear risk was found
with respect to detection bias (blinding of outcome
assessment) in another study (Ad26.COV2.S vaccine).
With regard to the characteristics of participants
included in the full analysis set and divided into vac-
cine and placebo groups, the mean age and propor-
tion of male/female subjects appears comparable
among the three studies in both vaccine and placebo
groups. It is noteworthy that the ethnicity most
represented in all three studies is Caucasian
(Supplementary Tables 2 and 3).
The total number of subjects included in the safety
population set for BNT162b2 was 8080 (4040 in both
the vaccine and placebo groups), for mRNA-1273 was
30323 (15168 in the vaccine group and 15155 in the pla-
cebo) and for Ad26.COV2.S was 6736 (3356 in the vac-
cine group and 3380 in the placebo group). The number
and percentage (95 % CI) of AEs across the different
groups are reported in tables 2 and 3 considering active
and placebo recipients, respectively. The percentage of
AEs for different age groups of all trials are reported in
the Supplementary Table 4.
RRs showed that, in each study, the probability of
occurrence of almost all AEs reported in the vaccine
groups was higher compared to the placebo groups
(Table 4).
The most frequently solicited AEs in the active and
placebo groups were fatigue, headache, local pain as
injection site reactions, and myalgia/muscle pain.
In particular, considering the first doses, fatigue was
reported by 42% and 37% subjects after the first dose of
BNT162b2 and mRNA-1273 respectively, and by 38% of
the single dose of Ad26.COV2.S. The percentage of sub-
jects reporting fatigue in the placebo group was 29%
and 27% for the first dose of BNT162b2 and mRNA-3
BNT162b2 mRNA-1273 AD26.COV2.S
Systemic reactions
Arthralgia / Joint Pain Joint pain Arthralgia
Chills Chills Chills
Fatigue Fatigue Fatigue Fatigue
Fever Fever Fever Fever
Headache Headache Headache Headache
Myalgia / Muscle pain Muscle pain Myalgia Myalgia
Nausea / Vomiting Vomiting Nausea / Vomiting Nausea




Local injection site reactions
Local Erythema / Redness Redness Erythema (redness) Erythema
Local Pain Pain Pain Pain
Local Swelling Swelling Swelling Swelling
Table 1: Solicited adverse events categories (n = 11) observed in the vaccine and the placebo groups (reported in at least two out of the
three included studies) divided into systemic reactions and local injection site reactions.
a The categorization into eleven categories follows the classification of solicited AEs
b The antipyretic/analgesic use is a systemic reaction effect considered as an AE in the selected trials
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1273 trials respectively, and 21% for the single dose of
Ad26.COV2.S trial.
After the first dose, headache was reported by 35% of
the BNT162b2 vaccine group and by 33% of the mRNA-
1273 vaccine group. For the unique dose of Ad26.
COV2.S vaccine, 39% of the subjects experienced head-
ache. About 27% of placebo groups of BNT162b2 and
mRNA-1273 reported headache after the first dose, while
24% of the subjects of the placebo group combined with
Ad26.COV2.S vaccine exhibited such AE after the
administration of the single dose.
As regards injection side reactions, local pain was
reported after the first dose by 79% and 84% of the
BNT62b2 and mRNA-1273 vaccine respectively, and by
49% of Ad26.COV2.S vaccine group after the single
dose. Local pain was reported after the first dose by 12%
and 17% of the subjects of the placebo groups combined
with BNT162b2 and mRNA-1273 vaccine groups respec-
tively, and by 17% of the placebo group combined with
Ad26.COV2.S vaccine after the administration of the
single dose.
Myalgia/muscle pain was reported by 18% of
BNT162b2 vaccine group subjects and 23% of
mRNA-1273 vaccine group participants after the first
dose, and by 33% of subjects who received a single
dose of Ad26.COV2.S. In the placebo groups, myal-
gia/muscle pain was reported by 10% and 14% of the
BNT162b2 and mRNA-1273 trials respectively, after
the first dose, and by 13% of Ad26.COV2.S after the
single-dose.
The most frequently reported adverse reaction in the
active groups was local pain, with a higher percentage
frequency observed for the mRNA vaccines (BNT162b2:
79%; mRNA-1273: 84%; Ad26.COV2.S: 49%); whereasfatigue (BNT162b2: 29%; mRNA-1273: 27%; Ad26.
COV2.S: 21%) and headache (BNT162b2: 27%; mRNA-
1273: 27%; Ad26.COV2.S: 24%) were the most com-
mon AEs among placebo recipients (Fig. 1).
After the first dose, a significant increase of fatigue
and headache was observed in younger subjects in the
placebo groups of the mRNA vaccines (CI: 0¢3 to 0¢4) in
comparison to the older groups. In contrast, the per-
centage of these adverse events (fatigue and headache)
in the younger and older recipients was similar for pla-
cebo group of the viral vector type vaccine. Considering
participants aged 18-54 years, fatigue and headache
were reported more in the placebo groups combined
with BNT162b2. Interestingly, in the vaccine recipients
local pain was the most reported symptom, as injection
site reaction, with a higher representation in the youn-
ger subjects (for the mRNA vaccines with a C.I. between
0¢7-0¢9, and for the viral vector type vaccine between
0¢3-0¢6). However, in the placebo recipients, this spe-
cific AE was reported in the same C.I., between 0¢1-0¢2,
in the two age groups and for all three vaccines. The sys-
temic side effect of myalgia/muscle pain was reported
in vaccine recipients in a C.I. between 0¢1 and 0¢4, with
a higher representation for younger subjects in the
three groups, and considering placebo recipients
between 0¢1-0¢2 for the two age groups (Fig. 2).
Finally, as shown in table 3, the percentage (95% CI)
with AEs was less after the second dose of placebo. Spe-
cifically, among the systemic reactions, fatigue, head-
ache, and myalgia/muscle pain were observed to a
lesser extent after the second doses of placebo in com-
parison to the first doses. Particularly, fatigue decreased
from 29% to 20% in the BNT162b2-associated group,
and from 27% to 23% in mRNA-1273-associated group.www.thelancet.com Vol xx Month xx, 2021
BNT162b2 mRNA-1273 AD26.COV2.S
1st dose (N = 4040) 2nd dose (N = 3705) 1st dose (N = 15168) 2nd dose (N = 14677) 1st single-dose (N = 3356)
AEs nAEs (%) 95% CI nAEs (%) 95% CI nAEs (%) 95% CI nAEs (%) 95% CI nAEs (%) 95% CI
Arthralgia/joint pain 406 (10¢0) 9¢1 ̶ 11¢0 772 (20¢8) 19¢5 ̶ 22¢1 2511 (16¢6) 16¢0 ̶ 17¢1 6284 (42¢8) 42¢0 ̶ 43¢6
Antipyretic/Analgesic use 996 (24¢7) 23¢3 ̶ 26¢0 1570 (42¢4) 42¢4 ̶ 44¢0 668 (19¢9) 18¢6 ̶ 21¢3
Any local AR 12765 (84¢2) 83¢6 ̶ 84¢7 13006 (88¢6) 88¢1 ̶ 89¢1 1685 (50¢2) 48¢5 ̶ 51¢9
Any systemic AEs 8320 (54¢9) 54¢1 ̶ 55¢6 11652 (79¢4) 78¢7 ̶ 80¢0 1850 (55¢1) 53¢4 ̶ 56¢8
Chills 434 (10¢7) 9¢8 ̶ 11¢7 1114 (30¢1) 28¢6 ̶ 31¢5 1253 (8¢3) 7¢8 ̶ 8¢7 6482 (44¢2) 43¢4 ̶ 45¢0
Fatigue 1700 (42¢1) 40¢6 ̶ 43¢6 2086 (56¢3) 54¢7 ̶ 57¢9 5635 (37¢2) 36¢4 ̶ 37¢9 9582 (65¢3) 64¢5 ̶ 66¢1 1283 (38¢2) 36¢6 ̶ 39¢9
Fever 111 (2¢7) 2¢2 ̶ 3¢3 512 (13¢8) 12¢7 ̶ 14¢9 115 (0¢8) 0¢6 ̶ 0¢9 2278 (15¢5) 14¢9 ̶ 16¢1 302 (9¢0) 8¢0 ̶ 10¢0
Headache 1413 (35¢0) 33¢5 ̶ 36¢4 1732 (46¢7) 45¢1 ̶ 48¢4 4951 (32¢6) 31¢9 ̶ 33¢4 8602 (58¢6) 57¢8 ̶ 59¢4 1306 (38¢9) 37¢3 ̶ 40¢6
Local erythema/redness 189 (4¢7) 4¢0 ̶ 5¢3 243 (6¢6) 5¢8 ̶ 7¢4 430 (2¢8) 2¢6 ̶ 3¢1 1257 (8¢6) 8¢1 ̶ 9¢0 245 (7¢3) 6¢4 ̶ 8¢2
Local pain 3186 (78¢9) 77¢6 ̶ 80¢1 2730 (73¢7) 72¢3 ̶ 75¢1 12690 (83¢7) 83¢1 ̶ 84¢3 12943 (88¢2) 87¢7 ̶ 88¢7 1632 (48¢6) 46¢9 ̶ 50¢3
Local swelling 250 (6¢2) 5¢4 ̶ 6¢9 256 (6¢9) 6¢1 ̶ 7¢7 932 (6¢1) 5¢8 ̶ 6¢5 1789 (12¢2) 11¢7 ̶ 12¢7 178 (5¢3) 4.5 ̶ 6¢1
Myalgia/muscle pain 738 (18¢3) 17¢1 ̶ 19¢5 1260 (34¢0) 32¢5 ̶ 35¢5 3441 (22¢7) 0¢22 ̶ 23¢4 8508 (58¢0) 57¢2 ̶ 58¢8 1113 (33.2) 31¢6 ̶ 34¢8
Nausea/vomiting 37 (0¢9) 0¢6 ̶ 1¢2 51 (1¢4) 1¢0 ̶ 1¢8 1262 (8¢3) 7¢9 ̶ 8¢8 2785 (19¢0) 18¢3 ̶ 19¢6 477 (14¢2) 13 ̶ 15¢4
Table 2: Safety set of solicited adverse events − any grade - reported in the active groups for mRNA-1273 for BNT162b2, mRNA-1273, and AD26.COV2.S.
Abbreviations: N= sample size. AEs= Adverse Events. n AEs= number of Adverse Events. CI= Confidence Interval. AR= Adverse reaction.
a 95% confidence intervals are indicated (inferior value of the interval - superior value of the interval).
b The bold lines represent the most frequently reported symptoms.

















1st dose (N = 4040) 2nd dose (N = 3699) 1st dose (N = 15155) 2nd dose (N = 14566) 1st single-dose (N = 3380)
AEs nAEs (%) 95% CI nAEs (%) 95% CI nAEs (%) 95% CI nAEs (%) 95% CI nAEs (%) 95% CI
Arthralgia/joint pain 247 (6¢1) 5¢4 ̶ 6¢9 170 (4¢6) 3¢9 ̶ 5¢3 1783 (11¢8) 11¢3 ̶ 12¢3 1569 (10¢8) 10¢3 ̶ 11¢3
Antipyretic/
Analgesic use
545 (13¢5) 12¢4 ̶ 14¢5 427 (11¢5) 10¢5 ̶ 12¢6 191 (5¢7) 4¢9 ̶ 6¢4
Any local AR 2997 (19¢8) 19¢1 ̶ 20¢4 2735 (18¢8) 18¢1 ̶ 19¢4 657 (19¢4) 18¢1 ̶ 20¢8
Any systemic AEs 6399 (42¢2) 41¢4 ̶ 43¢0 5323 (36¢5) 35¢8 ̶ 37¢3 1185 (35¢1) 33¢5 ̶ 36¢7
Chills 203 (5¢0) 4¢4 ̶ 5¢7 125 (3¢4) 2¢8 ̶ 4¢0 878 (5¢8) 5¢4 ̶ 6¢2 809 (5¢6) 5¢2 ̶ 5¢9
Fatigue 1172 (29¢0) 27¢6 ̶ 30¢4 756 (20¢4) 19¢1 ̶ 21¢7 4133 (27¢3) 26¢6 ̶ 28¢0 3403 (23¢4) 22¢7 ̶ 24¢0 728 (21¢5) 20¢2 ̶ 22¢9
Fever 27 (0¢7) 0¢4 ̶ 0¢9 14 (0¢4) 0¢2 ̶ 0¢6 44 (0¢3) 0¢2 ̶ 0¢4 43 (0¢3) 0¢2 ̶ 0¢4 20 (0¢6) 0¢3 ̶ 0¢9
Headache 1100 (27¢2) 25¢9 ̶ 28¢6 735 (19¢9) 18¢6 ̶ 21¢2 4027 (26¢6) 25¢9 ̶ 27¢3 3410 (23¢4) 22¢7 ̶ 24¢1 802 (23¢7) 22¢3 ̶ 25¢2
Local erythema/
redness
45 (1¢1) 0¢8 ̶ 1¢4 26 (0¢7) 0¢4 ̶ 1¢0 67 (0¢4) 0¢3 ̶ 0¢5 56 (0¢4) 0¢3 ̶ 0¢5 131 (3¢9) 3¢2 ̶ 4¢5
Local pain 488 (12¢1) 11¢1 ̶ 13¢1 372 (10¢1) 9¢1 ̶ 11¢0 2658 (17¢5) 16¢9 ̶ 18¢1 2477 (17¢0) 16¢4 ̶ 17¢6 564 (16¢7) 15¢4 ̶ 17¢9
Local swelling 32 (0¢8) 0¢5 ̶ 1¢1 16 (0¢4) 0¢2 ̶ 0¢6 52 (0¢3) 0¢3 ̶ 0¢4 49 (0¢3) 0¢2 ̶ 0¢4 53 (1¢6) 1¢1 ̶ 2¢0
Myalgia/muscle pain 398 (9¢9) 8¢9 ̶ 10¢8 260 (7¢0) 6¢2 ̶ 7¢9 2071 (13¢7) 13¢1 ̶ 14¢2 1809 (12¢4) 11¢9 ̶ 13¢0 430 (12¢7) 11¢6 ̶ 13¢8
Nausea/vomiting 37 (0¢9) 0¢6 ̶ 1¢2 30 (0¢8) 0¢5 ̶ 1¢1 1074 (7¢1) 6¢7 ̶ 7¢5 934 (6¢4) 6¢0 ̶ 6¢8 327 (9¢7) 8¢7 ̶ 10¢7
Table 3: Safety set of solicited adverse events - any grade - reported in the placebo groups for mRNA-1273 for BNT162b2, mRNA-1273, and AD26.COV2.S.
Abbreviations: N= sample size. AEs= Adverse Events. n AEs= number of Adverse Events. CI= Confidence Interval. AR= Adverse Reaction.
a 95% confidence intervals are indicated (inferior value of the interval - superior value of the interval).
b The bold lines represent both the most frequently reported symptoms and a decrease in reported adverse reactions following the second dose in comparison to the first dose (only the difference between mRNA-1273 groups for local
pain was not statistically significant).
















AEs Vaccine Active group Placebo group RR lower CI upper CI
N n_AEs (%) N n_AEs (%)
Arthralgia/joint pain BNT162b2 4040 406 (10¢05) 4040 247 (6¢11) 1¢644 1¢412 1¢914
mRNA-1273 15168 2511 (16¢55) 15155 1783 (11¢76) 1¢407 1¢330 1¢489
Ad26.COV2.S − − −
Antipyretic/analgesic use BNT162b2 4040 996 (24¢65) 4040 545 (13¢49) 1¢828 1¢662 2¢009
mRNA-1273 − − −
Ad26.COV2.S 3356 668 (19¢90) 3380 191 (5¢65) 3¢522 3¢021 4¢107
Any local AR BNT162b2 − − −
mRNA-1273 15168 12765 (84¢15) 15155 2997 (19¢77) 4¢256 4¢118 4¢398
Ad26.COV2.S 3356 1685 (50¢20) 3380 657 (19¢43) 2¢583 2¢393 2¢788
Any systemic AEs BNT162b2 − − −
mRNA-1273 15168 8320 (54¢85) 15155 6399 (42¢22) 1¢299 1¢269 1¢330
Ad26.COV2.S 3356 1850 (55¢12) 3380 1185 (35¢06) 1¢572 1¢488 1¢661
Chills BNT162b2 4040 434 (10¢74) 4040 203 (5¢02) 2¢138 1¢820 2¢511
mRNA-1273 15168 1253 (8¢26) 15155 878 (5¢79) 1¢426 1¢312 1¢550
Ad26.COV2.S − − −
Fatigue BNT162b2 4040 1700 (42¢08) 4040 1172 (29¢01) 1¢451 1¢366 1¢541
mRNA-1273 15168 5635 (37¢15) 15155 4133 (27¢27) 1¢362 1¢318 1¢408
Ad26.COV2.S 3356 1283 (38¢23) 3380 728 (21¢54) 1¢775 1¢643 1¢918
Fever BNT162b2 4040 111 (2¢74) 4040 27 (0¢67) 4¢111 2¢706 6¢246
mRNA-1273 15168 115 (0¢75) 15155 44 (0¢29) 2¢611 1¢846 3¢694
Ad26.COV2.S 3356 302 (8¢99) 3380 20 (0¢59) 15¢208 9¢697 23¢851
Headache BNT162b2 4040 1413 (34¢97) 4040 1100 (27¢23) 1¢285 1¢203 1¢372
mRNA-1273 15168 4951 (32¢64) 15155 4027 (26¢57) 1¢228 1¢186 1¢272
Ad26.COV2.S 3356 1306 (38¢91) 3380 802 (23¢73) 1¢640 1¢523 1¢766
Local erythema/redness BNT162b2 4040 189 (4¢67) 4040 45 (1¢11) 4¢200 3¢043 5¢796
mRNA-1273 15168 430 (2¢83) 15155 67 (0¢44) 6¢412 4¢962 8¢287
Ad26.COV2.S 3356 245 (7¢30) 3380 131 (3¢87) 1¢884 1¢532 2¢316
Local pain BNT162b2 4040 3186 (78¢86) 4040 488 (12¢08) 6¢529 5¢998 7¢106
mRNA-1273 15168 12690 (83¢66) 15155 2658 (17¢54) 4¢770 4¢605 4¢941
Ad26.COV2.S 3356 1632 (48¢63) 3380 564 (16¢68) 2¢914 2¢682 3¢166
Local swelling BNT162b2 4040 250 (6¢19) 4040 32 (0¢79) 7¢812 5¢421 11¢258
mRNA-1273 15168 932 (6¢14) 15155 52 (0¢34) 17¢908 13¢556 23¢656
Ad26.COV2.S 3356 178 (5¢30) 3380 53 (1¢56) 3¢383 2¢498 4¢579
Myalgia/muscle pain BNT162b2 4040 738 (18¢26) 4040 398 (9¢85) 1¢854 1¢655 2¢078
mRNA-1273 15168 3441 (22¢68) 15155 2071 (13¢66) 1¢660 1¢580 1¢745

























































































































































































































































































































































































ArticlesHeadache decreased from 27% to 20% in the
BNT162b2-associated group and from 27% to 23% in
mRNA-1273-associated group. Finally, myalgia/muscle
pain decreased from 10% to 7% in the BNT162b2-asso-
ciated group and from 14% to 12% in mRNA-1273-asso-
ciated group.
On the contrary, considering local pain as a specific
adverse reaction, we observed a decrease following the
second dose of placebo for the BNT162b2-associated
group (from 12% to 10%) and not for the mRNA-1273-
associated group.
Unsolicited AEs were more common in the vaccine
groups than in the placebo groups (BNT162b2: 27%
vs 12%; mRNA-1273: 22% vs 19%; Ad26.COV2.S: 13%
vs 12%). SAEs observed in the active and placebo
groups of the three different vaccines occurred at a
similar rate. Particularly, any type of SAEs was
reported in less than 1% of both vaccine and placebo
groups for all the trials (BNT162b2: 0¢6% vs 0¢5%;
mRNA-1273: 0¢5% vs 0¢6%; Ad26.COV2.S: 0.4% in
both vaccine and placebo groups). Interestingly, SAEs
considered related by the investigators to the adminis-
tration of the drug or placebo were < 0¢1% for all the
studies analyzed. Furthermore, deaths only occurred
in < 0¢1% in both vaccine and placebo groups
(Supplementary Table 5).Discussion
The aim of our study was to examine the phase III of
COVID-19 vaccines approved to date. To this end, we
analyzed the solicited AE profiles in the active and pla-
cebo groups, as recorded in the reactogenicity subsets.
In this review, we have shown, for the first time in
the literature, that inducing specific expectations in pla-
cebo recipients can provoke AEs in terms of systemic
and local symptoms.
We found that the solicited AEs profile in the placebo
arms of the studies is comparable to those of the vaccine
with which placebo was compared, although the percent-
age was higher with vaccine (as shown in table 4). Specif-
ically, some adverse reactions, such as fatigue, headache,
and pain (i.e., injection site reaction and myalgia), which
were the most common AEs in the active groups, were
also observed in the placebo groups, with a higher C.I.
for fatigue and headache reported in placebo recipients.
In particular, for the first doses in placebo recipients,
the most reported AEs were fatigue and headache, while
the most reported AEs in the vaccine group was local
pain.
Among the systemic reactions, fatigue, headache,
and myalgia/muscle pain were observed to a lesser
extent after the second doses of placebo, in comparison
to the first doses. Conversely, in the vaccine groups, we
observed an increase of almost all AEs following the sec-
ond dose, with the exception of local pain.www.thelancet.com Vol xx Month xx, 2021
Fig. 1. Percentage of fatigue, headache, local pain, and myalgia/muscle pain in the placebo groups. Percentage (95% CI) of solicited
AEs in the placebo groups of mRNA based vaccines (first doses) and viral vector vaccine considering fatigue, headache, local pain,
and myalgia/muscle pain.
ArticlesInterestingly, younger participants showed higher
reporting of fatigue and headache both in the placebo
groups of the mRNA vaccines and after the first doses.
Considering the total subset of participants, systemic
reactions of fatigue, headache, and myalgia decreased
substantially from the first to the second dose of placebo
combined with the mRNA vaccines (with the exception
of local pain for mRNA-1273, as injection site reaction).
Conversely, in the active groups, the same symptoms
increased substantially after the second doses (with the
exception of local pain for BNT162b2, as injection site
reaction).
We have considered AEs categorized in the ascertain-
ment strategy as structured recording, where symptoms
were collected using a checklist or diary cards. In particu-
lar, solicited AEs were recorded using electronic diaries,
through the assessment of systematic reactions and local
injection site symptoms. The recording of solicited AEs,
assessed in the placebo recipients after the first doses,
and included in a checklist, instead of spontaneous
reports or unsolicited symptoms, allowed us to analyze
the role of negative expectations in treatment outcomes.
In addition, the results of the second doses of vaccines
and placebos allowed us to investigate aspects not only
related to the negative expectations associated with a new
treatment, but also in terms of learning from previous
experience, as a conditioning phenomenon.www.thelancet.com Vol xx Month xx, 2021Non-pharmacodynamic factors, such as expectation
alone, analyzed in the placebo groups of the considered
trials after the first treatment dose, may have triggered
distressing symptoms—as an effect of the nocebo
phenomenon.1,17 Self-fulfilling prophecy is a phenome-
non whereby the belief that a future event will occur
contributes to the actual occurrence of that adverse reac-
tion. It plays a crucial role in modelling experiences and
can be considered causal, rather than simply
predictive.18,19 Such beliefs, as response expectations, can
influence health outcomes,19,20 as previously seen in aller-
gology, in the treatment of muscle tension, for gastrointes-
tinal disorders, and erectile dysfunction, in asthmatic
patients and during generic substitution.21−29 This phe-
nomenon may be particularly relevant during the current
state of pandemic emergency and when testing new
vaccines.30,31 Furthermore, it has been observed that the
reporting of AEs was more common in patients with nega-
tive expectations when taking a new drug.32 Fear and anxi-
ety of experiencing adverse reactions due to the treatment
may be increased. These observations are in line with what
has been previously reported with respect to non-live vac-
cines, as symptoms occurring after immunization are not
always caused by the vaccine itself, but may be due to nega-
tive expectation and linked to nocebo risks.10 These con-
cerns may have an impact on the proportion of AEs
reported in RCTs.In several studies of rituximab9
Fig. 2. Percentage of fatigue, headache, local pain, and myalgia/muscle in younger and older placebo recipients, compared to the
vaccine arms. Percentage (95% CI) of solicited AEs in younger and older placebo recipients, compared to the vaccine arms, of mRNA
based vaccines (first doses) and viral vector vaccine considering fatigue, headache, local pain, and myalgia/muscle pain.
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Articlesadministration for rheumatoid arthritis, the proportion of
AEs decreased by 50% with subsequent doses, and this
result, (without pharmacological explanation), could be
related to decreased anxiety in participants.33−35 This is in
line with what we observed for systemic reactions, such
as fatigue and headache in placebo recipients of the new
mRNA vaccines. These two systemic reactions were the
most represented solicited symptoms in placebo recipi-
ents and decreased after the second dose (with a decrease
also observed for myalgia). Notably, these symptoms
often occur in healthy people who do not take medica-
tion.36 In their study, considering different clinical condi-
tions, Howick and colleagues37 found that headache,
fatigue and myalgia were among the most frequently
reported systemic AEs in the placebo groups of the ana-
lyzed RCTs. It is interesting to note that in the vaccine
recipients at the first doses, the most reported AE was
local pain, while in the placebo recipients the more repre-
sented AEs were systemic reactions, such as fatigue and
headache. Moreover, considering the second doses, the
systemic AEs decreased in placebo recipients, while allthe solicited AEs increased in the vaccine groups. Such
aspect may be influenced by several factors, including
conditioning. Significantly, our results seem to suggest a
role for nocebo in systemic adverse reactions, as mild
symptoms, most of which are not vaccine related.
Data from our study support the hypothesis that a
substantial proportion of the AEs of COVID-19 vaccines
may be related to nocebo effects. The fairly high propor-
tions of placebo and vaccine recipients who have experi-
enced AEs, and the adverse reactions observed, may
suggest prevention strategies to promote a possible
greater adherence to the vaccination campaign. The
media and health professionals could potentially reduce
these side effects through positive framing and by rais-
ing awareness of the nocebo effect. Unfortunately, the
presence of the current infodemic risk,38 in which nega-
tive information related to clinical trials of COVID-19
vaccines, may lead to an escalation in the occurrence of
AEs.30,31,39 The Internet as a source of medical informa-
tion could lead to limited trust in new treatments.
Indeed, negative publicity of statin-induced myalgia haswww.thelancet.com Vol xx Month xx, 2021
Articlesled to high rates of statin discontinuation, use of sec-
ond-line agents, and increased rates of cardiovascular
events among participants of an RCT of the statin ator-
vastatin in the non-blind extension phase.40 On the
other hand, and more recommended as a way of pro-
ceeding, as it was suggested by Barnes et al.,41 the
empirical studies that analyzed positive framing empha-
sized how it is a promising strategy to reduce nocebo
effects. However, they also revealed some important
open questions, including the best method of commu-
nicating AEs, the optimal statistical presentation,
whether framing affects the perceived absolute risk of
side effects, and what psychological mechanisms under-
lie framing effects. The authors pointed out that future
research will be vital in understanding the circumstan-
ces in which framing is most likely to be effective.41 In
particular, awareness of the nocebo effect may lead to a
greater participation in the COVID-19 immunization
and to a greater protection from infection.29 Signifi-
cantly, pointing out that the anticipation or fear of an
adverse reaction can become a self-fulfilling prophecy
(by causing the misattribution of unrelated, pre-existing
symptoms to the drug being evaluated) may in itself
help to obviate the presentation of adverse reactions. It
may also be helpful to discuss the nocebo phenomenon
explicitly at the time of trial recruitment and to explain
how somatic symptoms caused by pre-existing medical
illnesses, or by anxiety, can be misattributed to an active
medication. In particular, strategies to minimize
nocebo-related risks and to improve adherence to vac-
cine inoculation should be considered and discussed to
possibly modify negative expectations associated with a
new treatment. Positive framing has previously been
shown to be an effective strategy to prevent AEs in the
influenza vaccination campaign.42,43 It would be useful
to focus on benefits rather than negative effects, e.g. by
highlighting the proportion of patients who usually tol-
erate the treatment well, without experiencing particu-
lar side effects. Significantly, it would be also crucial to
emphasize how the levels of occurrence of SAEs in the
analyzed trials were similar in vaccine and placebo
recipients, and how they were defined by the authors as
unrelated to vaccination and in line with the expected
background rate in the general population.14−16
Our study leads to the important hypothesis that
phase III trials of COVID-19 vaccines could cause the
nocebo effect and alter their safety outcomes. The emer-
gency authorization of SARS-CoV-2 vaccines also may
lead the population to fear and anxiety about the safety
of these new drugs, triggering negative expectations
associated with immunization.Limitations of the study
The limitation of this study is that the data are taken
from published articles with information provided in a
summary format and individual patient data were notwww.thelancet.com Vol xx Month xx, 2021available. In addition, the data obtained from the studies
represent a further criticality due to the short duration
of the phase III safety follow-up. The evaluation of long-
term safety studies cannot be done in the context of
maintaining a placebo group for the planned follow-up
period of two years after the second dose. This makes
the generalization of the results to the general popula-
tion more uncertain. Furthermore, as we considered 10
clinical trials in three selected studies, we could not per-
form a meta-analysis. Future studies should consider
and deeply explore the role played by nocebo effects in
order to improve patients’ adherence to these lifesaving
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